Navigation Links
New England Biolabs Develops Novel Polymerase with Ultra-High Fidelity and Minimal GC Bias
Date:8/8/2012

IPSWICH, Mass., Aug. 8, 2012 /PRNewswire/ -- New England Biolabs (NEB) has released a novel DNA polymerase, Q5 High-Fidelity DNA Polymerase, that provides the highest fidelity amplification currently available, while also offering robust amplification across the broadest range of amplicons, including those that are GC- and AT-rich.

(Photo:  http://photos.prnewswire.com/prnh/20120808/NE54308 )

(Logo:  http://photos.prnewswire.com/prnh/20090921/NE79207LOGO-b )

High fidelity amplification is essential for experiments whose outcome depends upon the correct DNA sequence, such as sequencing, SNP detection, protein expression and gene function studies. However, results from such amplifications can be compromised by a DNA polymerase incapable of evenly amplifying diverse types of sequences. For example, high-fidelity PCR of GC-rich regions and other challenging amplicons can lead to lower yields and even non-specific amplification. In addition, any bias in library amplification, associated with next generation sequencing, can lead to challenges in sequence assembly and even "missing" sequence, a problem of growing concern in the sequencing community.

NEB's novel polymerase is fused to the processivity-enhancing Sso7d DNA binding domain, which improves fidelity (more than 50-fold higher than Taq), speed, and performance reliability (amplifying targets up to 20 kb long with extension times as low as 10 seconds per kb). The Q5 buffer system has also been extensively optimized to provide robust performance across both high-GC and high-AT regions, as well as other challenging amplicons.

"High-fidelity polymerases have tended to be more susceptible to difficulties in the PCR amplification of GC-rich or other challenging amplicons. Q5 polymerase has dramatically reduced these limitations and raised the bar for high-fidelity DNA amplification," says Fiona Stewart, Ph.D., Product Marketing Manager at NEB.

A hot start version of the Q5 polymerase, which utilizes a synthetic aptamer for room-temperature set up, is also available. Both the Q5 and Q5 Hot Start DNA Polymerases are available as standalone enzymes or in 2X master mix format for added convenience. A separate formulation has also been developed specifically to meet the needs of amplification of next generation sequencing libraries (NEBNext® High-Fidelity 2X PCR Master Mix).

The discovery and development of high-fidelity polymerases has been, for many years, a key focus of NEB's research. Beginning with the discovery of Vent® DNA Polymerase from Thermococcus litoralis in 1990, and more recently the commercialization of Phusion® DNA Polymerase, NEB researchers have identified and developed a number of high-fidelity polymerases with differing processivities, speeds and degrees of accuracy. Q5 DNA Polymerase is the most recent and highest-performing enzyme to have been added to this list. For more information and supporting data on Q5 DNA Polymerase, visit www.Q5PCR.com.

About New England Biolabs


Established in the mid 1970's, New England Biolabs, Inc. is the industry leader in the discovery and production of enzymes for molecular biology applications and now offers the largest selection of recombinant and native enzymes for genomic research. NEB continues to expand its product offerings into areas related to PCR, gene expression, sample preparation for next generation sequencing, cellular analysis, epigenetics and RNA analysis. Additionally, NEB is focused on strengthening alliances that enable new technologies to reach key market sectors. New England Biolabs is a privately held company, headquartered in Ipswich, MA and has extensive worldwide distribution through a network of exclusive distributors, agents and six subsidiaries located in Canada, China, France, Germany, Japan and the UK. For more information about New England Biolabs visit www.neb.com


Phusion DNA Polymerase was developed by Finnzymes Oy, now a part of Thermo Fisher Scientific.
PHUSION® is a registered trademark and property of Thermo Fisher Scientific.
NEBNEXT® and VENTR® are registered trademarks of New England Biolabs.
Q5 is a trademark of New England Biolabs.


'/>"/>
SOURCE New England Biolabs
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. New England Biolabs Demonstrates Support for Interactive Scientific Literature by Collaborating with AQnowledge
2. New England Biolabs Signs Agreement with Synthetic Genomics Inc. to Launch Gibson Assembly™ Master Mix for Molecular and Synthetic Biology Applications
3. New research points to benefits of innovative cobas® HPV test for primary screening as Englands cervical cancer screening programme includes the test in current HPV "triage" rollout
4. New England Biolabs Introduces Polbase, an Information Repository of Scientific Data for Polymerase Researchers
5. UCLA-led research team develops worlds most powerful nanoscale microwave oscillators
6. Medi-Solve Coatings Develops Masking Process for Medical Devices
7. Union Equity, Inc.s Wholly Owned Subsidiary Develops Cream that Aids in Soothing the Symptoms of Chemotherapy
8. College Chairman And Prolific Inventor Develops Life-Saving, Real-Time Diagnostic Technologies
9. Harvards Wyss Institute develops DNA nanorobot to trigger targeted therapeutic responses
10. Quanterix Develops Microfluidic Consumable That Will Enable Next Generation Molecular Diagnostic Systems based on Single Molecule Array Technology
11. Ecology Coatings Develops Coatings Safe for Direct Contact with Food Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2017)... ... 21, 2017 , ... Boston Strategic Partners, Inc. (BSP), a ... and Outcomes Research (HEOR) and ‘big data’ to provide a variety of in-depth ... $3.0 trillion with nearly 1/3 spent on hospitalizations. BSP has access to real-world ...
(Date:8/17/2017)... , ... August 17, 2017 , ... ... stock market news outlet had provided a research update on Aytu Bioscience and ... TRT product. , According to Soulstring, prescription rates for Natesto® have more than ...
(Date:8/16/2017)... ... August 16, 2017 , ... While art and science are often thought ... than one might think. A Mesh Is Also a Snare, a group exhibition ... Science Center’s Esther Klein Gallery (EKG) on August 17 and run through September 30. ...
(Date:8/15/2017)... spending the past two years building a state-of-the-art technology which consolidates ... this platform to healthcare stakeholders (hospitals, foundations, biopharma companies etc.) who ... vis a vis their members, under their own brand. Three recent ... ... ...
Breaking Biology Technology:
(Date:4/11/2017)... 2017 No two people are believed ... New York University Tandon School of Engineering and ... that partial similarities between prints are common enough ... phones and other electronic devices can be more ... lies in the fact that fingerprint-based authentication systems ...
(Date:4/5/2017)... April 5, 2017 Today HYPR Corp. ... the server component of the HYPR platform is officially ... the end-to-end security architecture that empowers biometric authentication across ... has already secured over 15 million users across the ... of connected home product suites and physical access represent ...
(Date:3/30/2017)... , March 30, 2017  On April 6-7, 2017, ... the Genome hackathon at Microsoft,s headquarters in ... competition will focus on developing health and wellness apps ... Hack the Genome is the first hackathon ... The world,s largest companies in the genomics, tech and ...
Breaking Biology News(10 mins):